Sorin Group S.p.A. Launches SonR(R) Sensor Based Cardiac Resynchronization Therapy (CRT) Optimization System

VENICE, Italy--(BUSINESS WIRE)--Sorin Group (MIL:SRN) (Reuters Code: SORN.MI), a global medical company and a leader in the treatment of cardiovascular diseases, announced today at the Venice Arrhythmias 2011 Congress, CE Mark approval and the European commercial launch of its innovative SonR CRT optimization system. The SonR system includes the SonR hemodynamic sensor embedded in the SonRtipTM atrial pacing lead and the ParadymTM RF SonR CRT-D device. SonR is the first and only system to provide weekly automatic optimization during patient’s real life activities as an alternative to in-clinic manual echocardiography-based device optimization for improved CRT response3.